# Preoperative medical therapy for acromegaly: current knowledge and clinical significance

**Authors:** Dan He, Qinyi Wang, Zhifeng Sheng, Guohua Li

PMC · DOI: 10.3389/fendo.2025.1636047 · Frontiers in Endocrinology · 2026-01-02

## TL;DR

This review discusses preoperative medical treatments for acromegaly, a hormone disorder, and how new therapies and biomarkers may improve patient outcomes.

## Contribution

The paper provides a systematic summary of recent advancements and challenges in preoperative medical therapy for acromegaly.

## Key findings

- First-generation somatostatin receptor ligands show controversial efficacy in improving postoperative remission.
- New SRL formulations and molecular targets are expanding the therapeutic options for preoperative treatment.
- Advanced imaging and biomarkers may help better stratify patients for treatment.

## Abstract

Acromegaly is a chronic endocrine disorder characterized by excessive secretion of growth hormone (GH), predominantly caused by pituitary adenomas. Despite advancements in neurosurgical techniques, the surgical remission rates for invasive macroadenomas or giant adenomas remain unsatisfactory. Therefore, multimodal treatment strategies, including preoperative medical therapy (POMT), have been implemented to improve patient outcomes. Among these, first-generation somatostatin receptor ligands (fg-SRLs) have been the most extensively studied preoperative agents; however, their clinical efficacy in enhancing postoperative remission remains controversial. In recent decades, ongoing research into novel drugs and molecular targets are reshaping the therapeutic landscape of POMT. Beyond traditional clinical models and functional assays, the integration of advanced imaging modalities and molecular biomarkers promises to refine patient stratification, particularly for individuals with suboptimal responses to transsphenoidal surgery (TSS). Furthermore, novel SRL formulations and the identification of new molecular targets could further expand the therapeutic landscape of POMT. In this narrative review, we systematically summarize the latest research advancements in POMT for acromegaly and discusses potential therapeutic strategies and persisting obstacles in this field.

## Linked entities

- **Diseases:** acromegaly (MONDO:0019933)

## Full-text entities

- **Genes:** GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}
- **Diseases:** adenomas (MESH:D000236), Acromegaly (MESH:D000172), pituitary adenomas (MESH:D010911), endocrine disorder (MESH:D004700)
- **Chemicals:** SRL (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12807991/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12807991/full.md

## References

122 references — full list in the complete paper: https://tomesphere.com/paper/PMC12807991/full.md

---
Source: https://tomesphere.com/paper/PMC12807991